Sanofi's AlphaMedix Shows Promise in Treating GEP-NETs

Sanofi's AlphaMedix, an investigational targeted alpha therapy, has shown promising results in a phase 2 study for treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study, presented at the 2025 ESMO Congress, highlighted its potential for patients both naïve and exposed to radioligand therapy (RLT).

The phase 2 trial met all primary efficacy benchmarks, with an overall response rate (ORR) of 60% in RLT-naïve patients and 34.6% in those previously exposed. The drug demonstrates durable responses, with 72.3% progression-free survival over 36 months for naïve patients.

The safety profile was consistent across cohorts, though treatment-emergent adverse events occurred in all patients. Key results are encouraging further clinical advancement, with an international phase 3 study in the works.